Analytic Investors’s Supernus Pharmaceuticals SUPN Stock Holding History

Analytic Investors’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-100,196	Closed	-$1.53M	–	667
2016 Q1	$1.53M	Buy	100,196 +12,923	+15%	+$169K	0.02%	349
2015 Q4	$1.17M	Buy	87,273 +59,223	+211%	+$916K	0.01%	377
2015 Q3	$394K	Buy	+28,050	New	+$522K	0.01%	475

Other funds holding SUPN

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

RIM

Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

NPIC

Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Analytic Investors's SUPN Position: Q2 2016 in Review

Analytic Investors sold out of Supernus Pharmaceuticals (SUPN) in Q2 2016, closing a stake of 100,196 shares — an estimated $1.53M sold.

Analytic Investors first reported a position in SUPN in Q3 2015 and held it in 3 quarters. The position peaked at $1.53M in Q1 2016. 214 funds tracked by Wall St. Rank hold SUPN as of Q2 2016.

Analytic Investors reported no remaining Supernus Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Analytic Investors sold 100,196 Supernus Pharmaceuticals shares in Q2 2016, an estimated $1.53M.
Analytic Investors first reported a position in Supernus Pharmaceuticals in Q3 2015 and held it in 3 quarters.
Analytic Investors's Supernus Pharmaceuticals position peaked at $1.53M in Q1 2016.
214 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2016.

Based on Analytic Investors's 13F filing for Q2 2016, filed 11 Aug 2016.